Thiogenesis Therapeutics, Corp.
TTIPF
$0.585
$0.583436,462.50%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 19.02% | -41.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.60% | 6.34% | |||
| Operating Income | -32.60% | -6.34% | |||
| Income Before Tax | -39.66% | -22.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -39.66% | -22.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -39.66% | -22.10% | |||
| EBIT | -32.60% | -6.34% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -38.32% | -21.59% | |||
| Normalized Basic EPS | -38.06% | -21.82% | |||
| EPS Diluted | -38.32% | -21.59% | |||
| Normalized Diluted EPS | -38.06% | -21.82% | |||
| Average Basic Shares Outstanding | 0.62% | 0.59% | |||
| Average Diluted Shares Outstanding | 0.62% | 0.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||